ALNY

Trade Alnylam Pharmaceuticals, Inc. - ALNY stock price

1m
5m
15m
30m
1H
4H
1D
1W
History

ALNY

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia. Its clinical programs also include ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR, which is in the Phase I clinical trial for the treatment of various forms of ATTR amyloidosis; Lumasiran (ALN-GO1) that is in Phase I/II clinical trial for the treatment of primary hyperoxaluria type 1; and Cemdisiran (ALN-CC5), which is in the Phase II clinical trial for the treatment of complement-mediated diseases. The company has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc; and Regeneron Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
White Paper Declaration
iPhone Image
Trade the world’s top tokenised stocks, indices, commodities and currencies with the help of crypto or fiat
iMac Image
Trade the world’s top tokenised stocks, indices, commodities and currencies with the help of crypto or fiat
iMac Image
1BTC
Invest
20BTC
Profit
Leverage:
x20
The Power Of Leverage
Trade in the big leagues with 100 Bitcoin for every 1 Bitcoin you put in

ALNY price history

Date Close Change Change(%) Open High Low
Jan 21, 2022 136.12 4.83 3.68% 131.29 137.57 129.55
Jan 20, 2022 137.96 -6.49 -4.49% 144.45 146.01 137.62
Jan 19, 2022 138.20 -1.58 -1.13% 139.78 143.51 137.34
Jan 18, 2022 139.01 -5.57 -3.85% 144.58 146.05 138.27
Jan 14, 2022 148.05 3.05 2.10% 145.00 150.86 142.36
Jan 13, 2022 147.82 2.99 2.06% 144.83 150.20 144.50
Jan 12, 2022 147.21 1.37 0.94% 145.84 148.51 143.76
Jan 11, 2022 147.72 -0.85 -0.57% 148.57 151.82 146.16
Jan 10, 2022 149.68 3.97 2.72% 145.71 149.79 142.33
Jan 7, 2022 147.94 -1.89 -1.26% 149.83 152.83 147.25
Jan 6, 2022 150.74 -4.09 -2.64% 154.83 154.83 146.13
Jan 5, 2022 154.70 -5.87 -3.66% 160.57 162.68 154.19
Jan 4, 2022 165.01 -4.14 -2.45% 169.15 171.55 161.39
Jan 3, 2022 173.38 3.39 1.99% 169.99 173.69 164.82
Dec 31, 2021 169.39 -2.02 -1.18% 171.41 174.80 169.37
Dec 30, 2021 170.81 3.00 1.79% 167.81 174.00 167.80
Dec 29, 2021 169.72 1.50 0.89% 168.22 169.86 164.82
Dec 28, 2021 168.35 7.43 4.62% 160.92 171.67 160.92
Dec 27, 2021 160.90 -26.87 -14.31% 187.77 187.78 158.90
Dec 23, 2021 193.77 6.61 3.53% 187.16 195.76 185.08